Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorFrieder Schaumburg
About this trial
This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.
Eligibility criteria
Qualifiers
Adults (age ≥18 years);
Need for a treatment (incision/drainage ± antibiotic treatment po or iv) of an SSTI;
S. aureus causing SSTI identified from at least one clinical specimen (including isolation in polymicrobial cultures if S. aureus is considered to be the leading pathogen);
Onset of symptoms within the last 4 weeks;
Disqualifiers
Previous allergic reaction to clindamycin
Previous antibiotic-associated diarrhea
Previous study participation
Pregnancy as confirmed by a beta-HCG rapid test.
Trial design
Treatments tested in this trial
- Clindamycin
- Standard of care
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Frieder Schaumburg
Lead sponsor
Universität Münster
Sponsor institution
Source ClinicalTrials.gov